Salarius Pharmaceuticals, Inc. (SLRX) Q2 2021 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good day, ladies and gentlemen, and welcome to the second quarter 2021 Solaris Pharmaceuticals earnings webcast and conference call. At this time, our participants are in a listen-only mode. Later, we will conduct the question and answer session, and instructions will follow at that time. If anyone should require assistance during the conference, please press star, then zero on your touchtone telephone. I will now turn the conference over to your host, Mr. Jason Rando, with Tiberin's Strategic Advisors, please go ahead. Good morning, everyone, and thank you for joining Solaris Pharmaceuticals' 2021 second quarter and full year financial and corporate results call. Earlier this morning, Solaris Pharmaceuticals issued a press release detailing its financial results for the three months and the full year ended June 30th, 2021, which we encourage listeners to read. The press release can be found in the news section of solarisfarma.com. Solaris also filed a 10-Q this morning, which is available on solarisfarmer.com and sec.gov. Before beginning the call, I would like to make the following statement. Today, we'll be making certain forward-looking statements about operating metrics, future expectations, plans, events, and circumstances, including statements about our strategy, future operations, and the development and effectiveness of our lead investigational drug candidate, Sekla Demstat, and our expectations regarding our capital allocation and cash resources. These statements are based on current expectations, and you should not place undue reliance on these statements. Actual results may differ materially due to our risks and uncertainties, including those detailed in the risk factors section of Solaris Pharmaceuticals' annual report on Form 10-K for the year ended 202...